Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31617638 | 0.98 | GOT1 (0.37) | GOT1TRPV1KIF11P2RX7 | |
| SCHEMBL20128939 | 0.81 | GOT1 (0.35) | GOT1P2RX7 | |
| SCHEMBL85354 | 0.81 | GOT1 (0.35) | GOT1P2RX7 | |
| SCHEMBL19872223 | 0.81 | GOT1 (0.35) | GOT1P2RX7 | |
| SCHEMBL29083684 | 0.81 | GOT1 (0.35) | GOT1P2RX7 | |
| SCHEMBL23921186 | 0.78 | CTDSP1 (0.37) | GOT1P2RX7CTDSP1 | |
| SCHEMBL17307729 | 0.78 | GOT1 (0.33) | GOT1P2RX7SMN1; SMN2CTDSP1 | |
| SCHEMBL4357788 | 0.78 | GOT1 (0.33) | GOT1CTDSP1 | |
| SCHEMBL23196492 | 0.78 | GOT1 (0.33) | GOT1 | |
| SCHEMBL12495182 | 0.78 | GOT1 (0.42) | GOT1P2RX7NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568746-B1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20250236617-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4568746-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768401-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | REDX PHARMA PLC (GB) | 2025-01-21 | — | — | US | disclosed |
| CN-119013030-A | Inhibitors of CDK4/6 kinase | 金耐特生物制药公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2024-06-27 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070123505-A1 | Heterocycle-substituted 3-alkyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2007-05-31 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070099920-A1 | Benzimidazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| US-7202247-B2 | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | ATHEROGENICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | GOT1 2428/4885TRPV1 84/4885KIF11 2298/4885 |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | WNT1, WNT3, CTNNB1 | GOT1 3454/4885TRPV1 678/4885KIF11 4695/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | GOT1 2489/4885TRPV1 3435/4885KIF11 1892/4885 |
| US-20070123505-A1 | Heterocycle-substituted 3-alkyl azetidine derivatives | CNR1, CNR2, FAAH | GOT1 2463/4885TRPV1 73/4885KIF11 4181/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | GOT1 2226/4885TRPV1 610/4885KIF11 4550/4885 |
| US-20250236617-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | GRIN2C, CYP3A4, BICRA | GOT1 2734/4885TRPV1 182/4885KIF11 2175/4885 |
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | GOT1 2759/4885TRPV1 57/4885KIF11 2120/4885 |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | GOT1 698/4885TRPV1 1893/4885KIF11 4529/4885 |
| US-20070099920-A1 | Benzimidazoles useful as inhibitors of protein kinases | PDK1, AURKC, PIM3 | GOT1 1728/4885TRPV1 4207/4885KIF11 738/4885 |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | GOT1 3441/4885TRPV1 1151/4885KIF11 3852/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | GOT1 3205/4885TRPV1 4779/4885KIF11 3394/4885 |
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | CLPP, TYR, MRPL21 | GOT1 278/4885TRPV1 2313/4885KIF11 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.